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Genome Editing
Who owns gene editing?
Patents in the time of CRISPR
New gene-editing technologies, like CRISPR, promise revolutionary advances in biology and medicine. 
However, several patent disputes in the USA and UK may have complicated who can use CRISPR. What 
does this mean for the future of gene editing?
Patents
Broadly speaking, inventions present an informational 
paradox: often, costly and burdensome research is 
required to bring them to fruition, but once developed 
the invention becomes known to the public. Without 
some law restricting the copying of these inventions, 
many researchers may not have the incentive to engage 
in foundational research in the first instance.
Since at least the fifteenth century, the solution 
to this problem has been some form of patents: 
government issued rights to inventors—rights that 
allow inventors, for a limited period of time, to prevent 
others from copying their inventions. To be clear, 
patents are not inventors’ rights to use and develop 
their own inventions; they are rights only to exclude 
others from copying them. Patents, consequently, 
are viewed as “limited rights, for a limited time”. 
Nonetheless, this limited right can be tremendously 
valuable. Many pharmaceutical patents, for example, 
are worth billions of dollars.
Not all inventions deserve patent protection. 
Precisely because patents can be so valuable—and 
because patentees can essentially exclude others from 
developing certain areas of technology—patent laws 
throughout the world have established certain standards 
in an effort to ensure that only significant advances in 
science and technology receive patent protection. Today, 
Precisely editing the genetic code of living organisms 
has long been a supreme ambition of biologists. 
Editing the genome has the potential to cure genetic 
diseases, revive extinct species and combat public 
health crises, among other advances. The potential 
for the technology seems limited only by the human 
imagination. Previous efforts in the area, however, 
have proven less than satisfactory .
A recent advance in one gene-editing technology, 
Clustered Regularly Interspaced Short Palindromic 
Repeats—better known as CRISPR—may bring 
biologists’ ambitions to fruition. This precision-
editing system has so far lived up to its hype: CRISPR 
has been demonstrated to work in virtually every cell 
type attempted and appears almost infinitely flexible 
in modification .
But the promise of the technology has generated 
a patent dispute among the technologies’ creators: 
Jennifer Doudna of the University of California, 
Berkeley, and Emmanuelle Charpentier, now at the 
Max Planck Institute for Infection Biology in Berlin, 
on one side, and Feng Zhang of the Broad Institute, 
on the other. Resolving the patent dispute may 
ultimately decide who owns the rights to this crucial 
piece of biotechnology. This article outlines the law 
surrounding patents on biotechnology and explains 
the contours and effects of the current CRISPR 
patent disputes.
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in the USA and UK, patents may be granted only for 
inventions that are new, useful and “inventive” or “non 
obvious.” In addition, patentees must sufficiently disclose 
their inventions to the public—enough to enable others 
to make and use the invention. To meet these twin aims, 
patents, as documents, contain two parts: a written 
description of the invention, known as the specification, 
and the claims, short statements identifying the “metes 
and bounds” of the invention. The claims, in essence, 
define the patented invention.
In this way, the current system of patents ideally 
does double-duty in breaking the informational 
paradox of inventions. It encourages researchers to 
invest in expensive research by holding up the reward 
of a patent if they are successful. And it also requires 
inventors to disclose the fruits of that research to the 
public. Today, for better or worse, patents form an 
integral part of the research and development lifecycle 
for a host of industries.
The CRISPR patent dispute
Patent law has long faced the problem of 
contemporaneous invention: what to do when two 
inventors contemporaneously invent the same or 
a similar invention and each file competing patent 
applications? In much of the world, administrative 
efficiency dictates that the patent should be awarded to 
the first person to file. But, up until 2013 in the USA, 
the USA Patent and Trademark Office (PTO) awarded 
the patent to the first inventor . This presented several 
problems for the PTO—especially where, because of 
quirks of timing at the Patent Office, a later inventor 
but earlier filer was awarded the first patent. Through a 
restrictive reading of the patent statute, this circumstance 
potentially blocked the first inventor’s patent application 
from being awarded.
The current CRISPR dispute involves similar 
difficulties. Doudna and Charpentier filed an early 
patent application covering a limited form of the 
CRISPR technology in May 2012.  Zhang filed a similar 
application seven months later, in December 2012. But 
Zhang’s attorneys requested that the PTO “fast-track” 
his application: a procedure allowed—for a fee—on 
shorter, less contentious applications. Zhang’s attorneys’ 
strategy worked and, as a result, Zhang was awarded his 
first patent in April 2014 and over a dozen more by the 
following year. During this time, however, Doudna and 
Charpentier’s application suffered numerous technical 
difficulties at the PTO. And through much of 2014, it 
appeared that Zhang’s issued patents would block their 
applications, even though the duo had good claims as 
both the first inventors and first filers.
In April 2015, with the CRISPR patent race slipping 
away from them, Doudna’s attorneys requested that the 
PTO declare an interference proceeding: a trial, within 
the PTO, to determine the first inventor of a disputed 
technology. After receiving a recommendation from the 
patent examiner responsible for Doudna and Charpentier’s 
application, the PTO formally instituted an interference 
proceeding in January 2016 .
At its core, the interference proceeding is designed 
to answer who invented what, first. To do that, a three-
judge panel at the PTO will receive evidence concerning 
what Doudna, Charpentier and Zhang did in their 
laboratories, what they disclosed in their original patent 
applications and how an average molecular biologist 
would have viewed this information as the technology 
progressed through 2012. In addition, the panel 
must determine exactly which parts of Doudna and 
Charpentier’s application overlap with Zhang’s patents. 
To aid them in that determination, the panel drafts a 
“count,” a hypothetical patent claim that covers both 
sets of technologies. Moving forward, the scientists’ 
attorneys will file several sets of motions arguing that the 
count does or does not cover the technology in dispute, 
or that the count needs to be rewritten or broken up 
into several pieces to cover the contested inventions. In 
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addition, the attorneys will also file motions arguing that 
their respective clients were, in fact, the first to invent the 
CRISPR technology. The panel’s ruling on these motions 
should come in January 2017 if not earlier.
Outside of the USA, however, no analogue to 
interference proceedings exists. European patent offices 
faced with the contemporaneous invention problem 
simply award the patent to the first filer. But there are 
other procedures to contest already issued patents at 
their respective patent offices. At the European Patent 
Office, for example, anyone may file an opposition 
to a patent issued within nine months, arguing that 
the granted patent fails the novelty, inventive step or 
disclosure requirements. This has, in fact, happened 
with the CRISPR technology, where, to date, nine 
entities—including one company, CRISPR Therapeutics, 
founded by Charpentier—have filed oppositions to one 
of Zhang’s European patents. Decisions in those cases 
are not expected until the end of 2017, at the earliest. 
These disputes—both in the USA and elsewhere—
concerning control of the CRISPR technology suggest 
that ownership over the CRISPR patents will take years 
to unravel, and will result in a complicated system of 
patent rights throughout the world.
The future of CRISPR research
The patent disputes over CRISPR will likely have significant 
impact over the future of research in the area. First and 
foremost, the disputes may very well affect the funding 
of companies currently engaged in CRISPR research. A 
recent Bloomberg report by Caroline Chen and Doni 
Bloomfield noted that several drug manufacturers have 
entered into funding arrangements with various CRISPR 
start-ups, some worth hundreds of millions of dollars. The 
companies currently developing CRISPR either have a 
direct stake in the outcome of the current patent dispute or 
could be affected if the ultimate victor decides to enforce its 
patents against them. As a consequence, the patent dispute 
may shape which companies are allowed to commercially 
develop the CRISPR technology.
Second, the patent dispute may also alter which 
research institutions continue to study CRISPR as 
a gene-editing technology. Well-heeled research 
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institutions that cannot come to a license agreement 
with the eventual owner of the CRISPR patents may find 
themselves on the outside, looking in. This is important 
to mention—especially in the USA—because, contrary 
to popular belief, there is no “research exemption” for 
patent infringement. In Europe, however, such research 
exemptions do exist under the national laws of each 
country, but may be limited where academic institutions 
partner with commercial developers.
Third, the CRISPR patent dispute, no matter 
which way it turns, may signal a fundamental shift 
in the litigation and enforcement of foundational 
biotechnology. Most revolutions in molecular biology—
like recombinant DNA, PCR and RNAi—have been 
patented. And almost without exception, those 
technologies have been subject to free and easy licenses. 
But the CRISPR patent dispute appears to be shaping 
up to something different. It may very well signal a 
culture shift in academic research institutions from 
pure and translational research into profit-maximizing 
commercialization. While this is not altogether bad, it’s 
likely to conflict with universities’ broader educational 
missions to the public. As a result, which aspects of 
CRISPR will become subject to research, and by whom, 
may turn on those universities’ financial interests in 
developing certain CRISPR technologies rather than 
their scientific or therapeutic importance.
Taken together, these shifts may complicate the 
future of gene editing. It may be difficult, for example, 
simply to determine whether one is infringing one of 
the variety of patents covering gene-editing technology. 
And even if the CRISPR patent disputes produce a clear 
winner, it is unclear how the victor will deploy licenses, 
to whom and at what price. Furthermore, gene editing, 
and CRISPR in particular, is progressing so rapidly that 
is unclear whether new developments will be covered 
by the current landscape. As one example, the count at 
issue in the USA interference proceeding requires the 
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“hybridization” of a guide RNA and a tracrRNA . But 
it’s unclear whether this allows the RNAs to exist in two 
separate pieces or if they need to be linked, covalently or 
by sequence, somehow.
To both of their credits, Doudna and Zhang have 
supported some “open science” protocols by making 
CRISPR constructs available through an online 
repository called AddGene. In that way, the scientists 
are engaging in that most noble of scientific practices: 
the sharing of results. But it remains unclear how their 
benevolence jibes with their patents and the current 
patent dispute. It is likely that the litigation will need to 
be resolved first.
Gene editing, and CRISPR in particular, heralds 
a foundational advance in molecular biology. Like 
previous advances in biotechnology, CRISPR is subject 
to several patents and is at the centre of a current wide-
ranging patent dispute. But the current patent dispute 
surrounding CRISPR seems quite different from past 
cases. Even with a clear winner, the CRISPR patent 
dispute may ultimately complicate who can practise 
the technology going forward. It seems, then, that the 
development of CRISPR as a technology is a study as 
much of law as science.  ■
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